Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder

Athanasios Markopoulos¹, Antonio Inserra¹, Danilo De Gregorio† and Gabriella Gobbi¹,2*

¹Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, QC, Canada, ²McGill University Health Centre, McGill University, Montreal, QC, Canada

Recent clinical and preclinical evidence points towards empathogenic and prosocial effects elicited by psychedelic compounds, notably the serotonin 5-HT₂A agonists lysergic acid diethylamide (LSD), psilocybin, N,N-Dimethyltryptamine (DMT), and their derivatives. These findings suggest a therapeutic potential of psychedelic compounds for some of the behavioural traits associated with autism spectrum disorder (ASD), a neurodevelopmental condition characterized by atypical social behaviour. In this review, we highlight evidence suggesting that psychedelics may potentially ameliorate some of the behavioural atypicalities of ASD, including reduced social behaviour and highly co-occurring anxiety and depression. Next, we discuss dysregulated neurobiological systems in ASD and how they may underlie or potentially limit the therapeutic effects of psychedelics. These phenomena include: 1) synaptic function, 2) serotonergic signaling, 3) prefrontal cortex activity, and 4) thalamocortical signaling. Lastly, we discuss clinical studies from the 1960s and 70s that assessed the use of psychedelics in the treatment of children with ASD. We highlight the positive behavioural outcomes of these studies, including enhanced mood and social behaviour, as well as the adverse effects of these trials, including increases in aggressive behaviour and dissociative and psychotic states. Despite preliminary evidence, further studies are needed to determine whether the benefits of psychedelic treatment in ASD outweigh the risks associated with the use of these compounds in this population, and if the 5-HT₂A receptor may represent a target for social-behavioural disorders.

Keywords: autism, psychedelics, behaviour, neurobiology, LSD

INTRODUCTION

Autism spectrum disorder (ASD) is a neurodevelopmental condition affecting 1–2% of the global population (Chiarotti and Venerosi, 2020). ASD is often diagnosed in childhood, with individuals displaying characteristic atypicalities in social communication and interaction, as well as repetitive patterns of behaviour and restricted interests (American Psychiatric Association, 2013). These features are highly heterogeneous in ASD and are often accompanied with co-occurring diagnoses of depression and anxiety (Rai et al., 2018; Hollocks et al., 2019). At present, there is a lack of selective medications targeting the major phenotypes of ASD: impaired social behaviour and communication.

Psychedelics are currently experiencing a resurgence of scientific investigation, following in the footsteps of pioneering mid-twentieth century research. Although the term “psychedelic” encompasses a variety of compounds, the present review focuses on the serotonergic, or...
“classical,” psychedelics, which produce their hallucinogenic effects via the serotonin 5-HT_{2A} receptor (De Gregorio et al., 2016a; Holze et al., 2021b; Inserra et al., 2021a). These include lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT), and their derivatives (which will be hereafter referred to as “psilocedrins”). Other non-serotonergic psychedelics, such as the empathogen 3,4-Methylenedioxymethamphetamine (MDMA), have also been shown to increase social behaviour and empathy (Bedi et al., 2010; Hysek et al., 2014; Heifets and Malenka, 2016), and to reduce social anxiety in individuals with ASD (Danforth et al., 2018). However, due to MDMA’s vastly different pharmacological properties from serotonergic psychedelics, it will not be discussed in the present review.

Recent clinical and preclinical research demonstrates that psychedelics may hold therapeutic value in the treatment of some of ASD’s core features. Despite the emergence of compelling research, early clinical trials carried out in the 1960s and 70s revealed a variety of side effects after psychedelics were administered experimentally to children with ASD. Thus, the risks associated with the use of these compounds must be carefully examined when considering their potential use in neuroatypical individuals.

**CORE BEHAVIOURAL ATYPICALITIES AND CO-OCCURRING CONDITIONS**

ASD diagnoses are contingent on atypicalities in social behaviour. Clinical manifestations include a preference for non-social stimuli (Gale et al., 2019), aberrant non-verbal social behaviours (Osterling et al., 2002), and decreased attention to social stimuli (Sasson and Touchstone, 2014). Due to this diagnostic criterion, no selective treatments for ASD target these core traits. Instead, antipsychotics, antidepressants, mood stabilizers, and stimulants are used to target ASD-associated features, such as irritability, anxiety, and depression (DeFilippis and Wagner, 2016).

It is increasingly apparent that psychedelics enhance social behaviour and elicit empathogenic effects in healthy individuals (see Table 1 for a summarized list of recent clinical trials assessing the use of psychedelics in individuals without ASD). For instance, two psilocybin therapy sessions increased extraversion and openness for up to 3 months in individuals with treatment-resistant depression (Erritzoe et al., 2018). Similarly, a single administration of LSD enhanced sociability and the desire to be with others, while also increasing feelings of trust, closeness, and empathy (Dolder et al., 2016). Another recent study demonstrated that LSD acutely increases emotional empathy and blood levels of oxytocin, a neuropeptide implicated in social behaviour (Churchland and Winkielman, 2012; Holze et al., 2021a). These results have also been corroborated by preclinical evidence, which demonstrate that both acute (Vesuna et al., 2020) and repeated LSD (De Gregorio et al., 2021) enhanced social behaviour in mice.

ASD is often accompanied by depression, generalized anxiety, and social anxiety in particular (Spain et al., 2018; Hollocks et al., 2019; Kirsch et al., 2020). These co-occurring diagnoses may also be potential targets of psychedelics. For instance, LSD (Gasser et al., 2014) and psilocybin (Griffiths et al., 2016) have been shown to reduce symptoms of anxiety and depression in patients with life-threatening conditions. Importantly, the anxiolytic effect produced by LSD was appreciable after only two psychedelic-assisted therapy sessions and lasted for up to 12 months without any serious adverse effects; while the attenuative effects of psilocybin occurred after only one dose and were still present 6-months post-administration. Likewise, psilocybin has been shown to reduce depressive symptoms in those with treatment-resistant depression for up to 6 months (Carhart-Harris et al., 2018; Davis et al., 2021). The antidepressant and anxiolytic properties of DMT and ayahuasca have been observed similarly both clinically (Osório Fde et al., 2015; Palhano-Fontes et al., 2019) and pre-clinically (Cameron et al., 2019). It cannot be ruled out that the prosocial effects of psychedelics may reflect their anxiolytic effects, notably with regard to social anxiety.

Further, a recent double-blind randomized trial found that the antidepressant effects of psilocybin were not significantly different than those of the selective serotonin reuptake inhibitor (SSRI) escitalpram (Carhart-Harris et al., 2021). This result, in addition to the lack of a placebo-controlled group, limits support for the efficacy of psilocybin and highlights the importance of assessing whether or not the relative benefits of psychedelics (compared to established medications) warrant their potential side effects.

Despite ongoing research, there is still a lack of systematic, double-blind, placebo-controlled clinical trials assessing the specific therapeutic and adverse effects of psychedelics in neurotypical individuals and in those with ASD. Thus, further research is needed to identify an optimal dose that both minimizes the risk of adverse effects, and importantly, to elucidate whether or not the therapeutic effects of psychedelics observed in neurotypical individuals can be clinically observed in those with ASD. Further research is also needed to better understand how the effects and mechanisms of action associated with psychedelics differ when administered acutely or chronically, and to what extent such interventions provide therapeutic effects for people with ASD.

**NEUROBIOLOGY**

Due to the heterogeneity of ASD, the neurobiological underpinnings of its behavioural phenotypes remain difficult to characterize. ASD is diagnosed according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, including individuals with genetic and non-genetic etiologies across the spectrum. This presents an inherent challenge in hypothesizing how individuals with ASD might respond to psychedelic administration, given that ASD diagnoses cover a large spectrum of neurobiological and genetic profiles.

It is important to note that due to the lack of recent studies assessing the use of psychedelics in ASD, the following discussion reflects neurobiological processes that represent potential targets.
of psychedelics in ASD, not phenomena which have been proven to be associated with their effects in this population.

**Synaptic Function**

Many genes associated with ASD play integral roles in synaptic function (Guang et al., 2018), suggesting a critical involvement of synaptic dysfunction in ASD pathogenesis. Mutations in the SH3 and Multiple Ankyrin Repeat Domains (SHANK3) gene—encoding a synaptic scaffolding protein—can cause ASD (Durand et al., 2007). In a transgenic mouse model, this mutation produced a lengthening of dendritic spines and long-term potentiation deficits in the hippocampus (Wang et al., 2011). Mutations in the Contactin-Associated Protein-Like 2 (CNTNAP2) gene can also result in ASD (Penagarikano and Geschwind, 2012). CNTNAP2 encodes a synaptic cell-adhesion protein, and its deletion leads to altered dendritic arborization, spine development, and global synaptic transmission in mice (Anderson et al., 2012; Lazaro et al., 2019). Hyper-methylation of the Fragile X Mental Retardation 1 (FMR1) gene—which encodes an important regulatory protein for dendritic mRNA—is an epigenetic modification that can cause ASD (Bassell and Warren, 2008). FMR1 knockout rats display decreased hippocampal long-term potentiation and long-term depression, in addition to impaired α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated synaptic strength (Tian et al., 2017). Recently, ASD-induced synaptic impairments have also been identified in human-derived samples. Induced pluripotent stem cell-derived neurons from individuals with ASD exhibited reduced miniature excitatory post-synaptic current frequency and impaired N-Methyl-D-aspartic acid (NMDA) receptor function (Ross et al., 2020).

Given that alterations in synaptic properties are consistently found in different mouse models of ASD and recently in humans, the ability of psychedelics to modulate synaptic events might play an important role in their potential therapeutic effects in ASD. Recently, a single administration of psilocybin in mice was shown to produce AMPA receptor-mediated synaptic strengthening in hippocampal brain slices (Hesselgrave et al., 2021); an effect which may normalize the synaptic dysfunction of FMR1 knockout rats (Tian et al., 2017). Additionally, LSD and DMT were shown to promote structural and functional neuronal plasticity in rodent neuronal cultures and in Drosophila larvae (Ly et al., 2018). This study demonstrated that the increased dendritic arbor complexity, dendritic spine growth, and synaptic formation caused by psychedelics were mediated by the mammalian target of rapamycin (mTOR)- and 5-HT\textsubscript{2A}-signaling. Accordingly, our study revealed that LSD requires intact mTOR signaling in excitatory neurons and intact 5-HT\textsubscript{2A} neurotransmission in the mPFC to enhance social behaviour (De Gregorio et al., 2021). Given that mTOR (Hoeffer and Klann, 2010; Li et al., 2010) and the 5-HT\textsubscript{2A} receptor (Barre et al., 2016; Berthoux et al., 2019) play important roles in mediating neuroplastic events, LSD’s ability to increase social behaviour might be contingent on its ability to modulate neuroplasticity.

Despite the pronounced neurotrophic effects of psychedelics, the dysregulation of mTOR and 5-HT\textsubscript{2A} signaling in individuals with ASD may be a limiting factor for the therapeutic action of psychedelics on synaptic structure and function. For instance, hyperactive mTOR signaling was found in T cells isolated from children with ASD (Onore et al., 2017) and in post-mortem ASD brain samples (Tang et al., 2014). Positron emission tomography (PET) imaging studies have also revealed that individuals with ASD have reduced 5-HT\textsubscript{2A}-binding affinity in various brain regions compared to neurotypical individuals, suggesting a reduced expression of this receptor (Murphy et al., 2006; Oblak et al., 2013; Brandenburg and Blatt, 2019). In agreement, a significant overrepresentation of the G allele in the -1438 A/G polymorphism in the 5-HT\textsubscript{2A} gene was found in individuals with ASD (Hranilovic et al., 2010) and this has been associated with decreased receptor expression (Parsons et al., 2004; Myers et al., 2007). Given that mTOR and 5-HT\textsubscript{2A} mediate psychedelics’ synaptic effects, their dysregulation in ASD might limit or alter the therapeutic effects in these populations.

**Serotonin Signaling**

Serotonin (5-HT) is a neurotransmitter and hormone implicated in a variety of physiological phenomena and psychiatric conditions including neuronal development (Brummelte et al., 2016), synaptic plasticity (Kirkwood, 2000), depression (Cowen and Browning, 2015), and ASD (Chugani, 2002). Several lines of evidence suggest a dysregulation of the serotonergic system in ASD. Elevated blood serotonin levels was identified as one of the first putative biomarkers of ASD (Schain and Freedman, 1961), a finding that has been corroborated using meta-analysis, revealing that 28.3% of individuals with ASD have elevated 5-HT levels (Gabriele et al., 2014). Differences in 5-HT production have also been found in the brains of individuals with ASD. For instance, the development of brain serotonin synthesis capacity during childhood is robustly different in children with ASD (Chugani et al., 1999). Human studies generally point to lower levels of brain serotonin in ASD (Adamsen et al., 2014; D’Eufemia et al., 1995; McDougle et al., 1996; Nakamura et al., 2010). However, these studies have used proxy markers of serotonin levels such as PET binding of serotonin transporters and receptors, and cerebrospinal fluid serotonin metabolites. Thus, more direct studies are needed before low brain serotonin can be characterized as a biomarker of ASD. However, in support of this hypothesis are preclinical studies demonstrating that the depletion of brain serotonin in neonatal mice produces ASD-like behaviours such as altered social and stereotypical behaviours and increased anxiety (Boylan et al., 2007; Hohmann et al., 2007).

Interestingly, the 5-HT\textsubscript{1A} and 5-HT\textsubscript{2A} receptors may be key mediators of the role that serotonin signaling plays in the pathogenesis of ASD. Neuroimaging studies have found reduced binding affinity of these receptors in limbic and neocortical brain regions of individuals with ASD (Murphy et al., 2006; Oblak et al., 2013; Brandenburg and Blatt, 2019). Accordingly, mice with impaired 5-HT\textsubscript{1A} or 5-HT\textsubscript{2A} receptor expression or function display increased anxiety-like behaviour which is rescued with the selective genetic restoration of the respective receptor (Ramboz et al., 1998; Gross et al., 2002; Weissstub et al., 2006; Piszczek et al., 2015). LSD administration increases brain serotonin levels (Freedman,
The altered serotonin signaling observed in ASD. Given that psychedelics are agonists of the 5-HT_{1A} and 5-HT_{2A} receptors (De Gregorio et al., 2016a; Insera et al., 2021a), their pharmacological effects may help restore the altered serotonergic signaling observed in ASD.

Fenfluramine, a serotonin-releasing agent, enhances serotonin signaling in the brain. While few small-sample, placebo-controlled studies found moderate efficacy in fenfluramine’s ability to increase IQ in individuals with ASD (Geller et al., 1982; Ritvo et al., 1984), far more have found that this treatment is only effective in mildly reducing some of the motor and attentional atypicalities in people with ASD. This data suggests that increasing brain serotonin levels (and consequently serotonin signaling) is generally ineffective in improving the behavioural condition of individuals with ASD. Thus, the mechanisms of action of psychedelics must be better characterized in order to assess how they may interact with the altered serotonin signaling observed in ASD.

Prefrontal Cortex

The prefrontal cortex (PFC), and especially the medial PFC (mPFC), mediates social behaviours and cognition (Grossmann, 2013). Indeed, lesion of the PFC, which is clinically referred to as “frontal lobe syndrome,” induces profound deficits in social interaction (Anderson et al., 1999; Eslinger et al., 2004; Kim et al., 2015; Kirsch et al., 2020). Accordingly, reduced PFC activity is observed in various preclinical models of ASD (Krueger et al., 2011; Duffney et al., 2015; Brumback et al., 2018). Aberrant mPFC activity is also observed in human neuroimaging studies, which report altered mPFC recruitment and connectivity in individuals with ASD compared to neurotypical individuals (Kennedy and Courchesne, 2008; Lombardo et al., 2010; Li et al., 2020). Human post-mortem studies have also found that the PFC of children with ASD have greater neuronal disorganization and differences in neuronal composition compared to neurotypical children (Stoner et al., 2014; Hashemi et al., 2017).

Due to its high 5-HT_{2A} receptor expression, the PFC is highly modulated by the effects of serotonergic psychedelics (De Gregorio et al., 2021; Insera et al., 2021b; Jakab and Goldman-Rakic, 1998). Indeed, psychedelics activate unique 5-HT_{2A}-mediated transcriptional responses in the mouse mPFC (Martin and Nichols, 2016). Corroborating a crucial role of the mPFC in social behaviour, we demonstrated that the photoinhibition of mPFC excitatory neurons decreases sociability and blocks LSD’s prosocial effects (De Gregorio et al., 2021). Accordingly, in humans, mPFC activation was associated with LSD’s ability to enhance social adaptation to others whose opinions are similar to one’s own (Duerler et al., 2020). Another neuroimaging study revealed that psilocybin dampens mPFC neural activity, an effect correlated with the intensity of the subjective effects (Carhart-Harris et al., 2012). Similarly, LSD reduced the activity of the right mPFC in individuals presented with fearful faces (Mueller et al., 2017).

Although it is not clear which specific biological processes in the PFC may be targeted in ASD by psychedelics, signaling in this brain region plays an important role in the mechanism through which these compounds modulate social behaviour.

Thalamocortical Circuit

The thalamus plays a significant role in the integration of external and internal stimuli, and its projections to the cerebral cortex are believed to play a vital role in consciousness (Llinas et al., 1998; Redinbaugh et al., 2020). Thus, thalamocortical dysfunctions can interfere with complex human behaviours, such as social functioning. Recent studies have employed large, multi-site neuroimaging datasets to assess thalamocortical functional connectivity in ASD.

Given the vast heterogeneity of the ASD spectrum and that some of these studies considered the thalamus with other brain regions as a single subcortical structure in their analysis (Cerliani et al., 2015; Maximo and Kana, 2019), there are some inconsistencies in the literature. Nevertheless, two main connectivity trends are appreciable in individuals with ASD: 1) hyperconnectivity between the thalamus and sensorimotor cortex (Di Martino et al., 2014; Cerliani et al., 2015; Woodward et al., 2017; Maximo and Kana, 2019; Tomasi and Volkow, 2019; Ayub et al., 2021), suggesting an anomalous filtering of sensory information; and 2) hypoconnectivity between the thalamus and multimodal association cortices (Nair et al., 2013; Chen et al., 2016; Maximo and Kana, 2019), suggesting an aberrant integration of sensory information.

The effect of psychedelics on functional thalamocortical connectivity in humans has recently been investigated. Some studies demonstrate a general 5-HT_{2A}-mediated increase in thalamocortical connectivity following LSD (Tagliazucchi et al., 2016; Müller et al., 2017), while others show that psychedelics increase or decrease thalamocortical connectivity depending on the cortical region observed (Preller et al., 2018; Preller et al., 2019). Specifically, Preller and others (2018) revealed that LSD increases thalamic connectivity to cortical sensory regions while decreasing its connectivity to associative areas. This specific finding suggests that LSD may potentially exacerbate the abnormal thalamocortical connectivity in individuals with ASD. Thus, more investigation is required to elucidate the link between thalamocortical connectivity and social behaviour in ASD, and the way that psychedelics mediate this link.

In addition to thalamocortical connectivity, the effects of psychedelics on social behaviour may involve the regulation of spontaneous firing of thalamic neurons. The mediodorsal nucleus of the thalamus (MDT) has extensive reciprocal projections to the mPFC and is implicated in various cognitive functions, including sociability (Ferguson and Gao, 2018; Parnaudeau et al., 2018). Individuals with ASD present with morphological thalamic alterations, such as decreased global thalamic volume (Tsatsanis et al., 2003; Waiter et al., 2004), and increased surface area of the MDT specifically (Schuetze et al., 2016). Interestingly, the pharmacogenetic inhibition of MDT projections has been shown to reduce social preference in rats (Ferguson and Gao, 2018), further supporting this nucleus’s role in mediating social behaviour. We recently discovered that LSD increases neuronal firing in the MDT (Insera et al., 2021b), suggesting that LSD’s effects may partly be mediated by its modulation of MDT projections.
TABLE 1 | Recent (2008–2021) clinical trials assessing social behaviour-related effects of psychedelics in neurotypical (non-ASD) individuals

| Year | Title | Cohort | Design | Compound | Regimen (dose, frequency, route of administration) | Main outcomes | Side effects | Ref |
|------|-------|--------|--------|----------|--------------------------------------------------|---------------|-------------|-----|
| 2008 | Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later | Healthy volunteers with regular participation in religious/spiritual activities | Randomized, double-blind, placebo-controlled, within-subject | Psilocybin | 30 mg/70 kg once, twice or three times | Psilocybin increases altruistic/positive social effects at 14 months follow-up | None reported | Griffiths et al. (2008) |
| 2009 | A six-month prospective evaluation of personality traits, psychiatric symptoms and quality of life in ayahuasca-naive subjects | Volunteers participating in religious Ayahuasca rituals (18–57 y/o, average 35.7 y/o, n = 23, 8 males, 15 females) | Observational naturalistic study | Ayahuasca | Up to 12 times over 6 months | Regular ayahuasca users have higher “social connectedness” scores (the Short Form-36 Health Survey Questionnaire). Ayahuasca might lower social reward dependence by decreasing sensitivity to signals of social approval | None reported | Bakkes et al. (2009) |
| 2011 | Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects | Healthy volunteers (29–62 y/o, average 46 y/o, n = 18, 8 males, 10 females) | Randomized, double-blind, placebo-controlled, within-subject | Psilocybin | 0, 5, 10, 20, 30 mg/70 kg, per oral solution | Psilocybin increases altruistic/positive social effects at all doses tested | Psilocybin induces dose-dependent acute anxiety/fear (44% of volunteers report delusions or paranoid thinking sometimes during the session (especially at 30 mg/70 kg). Effects managed with reassurance in the supportive setting | Griffiths et al. (2011) |
| 2015 | Acute effects of lysergic acid diethylamide in healthy subjects | Healthy volunteer (25–51 y/o, average 28.6 y/o, n = 16, 8 males, 8 females) | Randomized, double-blind, placebo-controlled, within-subject | LSD | 200 μg, once, gelatin capsules | LSD increases ratings of “empathetic drug effects” such as “closeness to others,” “openness,” and “trust” | LSD increases circulating oxytocin level | Schmid et al. (2015) |
| 2016 | LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality | Healthy volunteer and mostly hallucogen-naive (20–65 y/o) volunteers, n = 40, 20 males, 20 females | Randomized, double-blind, placebo-controlled, within-subject | LSD | 100 μg, once, per oral solution 200 μg, once, per oral solution | LSD enhances explicit and implicit emotional empathy | LSD increases prosocial behaviour. LSD enhances the desire to be with others. LSD decrease cognitive empathy | None reported | Doblin et al. (2016) |
| 2016 | Effects of serotonin 2A/1A receptor stimulation on social exclusion processing | Healthy volunteers (20–37 y/o, average 26.72 y/o, n = 21, 12 males, 9 females) | Randomized, double-blind, placebo-controlled, within-subject | Psilocybin | 0.215 mg/kg, once, per oral solution | Psilocybin reduces the feeling of social rejection | Psilocybin decreases the neural responses to social exclusion in the dorsal anterior cingulate cortex and the middle frontal gyrus | None reported | Prober et al. (2016) |
| 2016 | Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial | Individuals with advanced stage II or IV cancer (n = 29) | Randomized, double-blind, placebo-controlled, within-subject | Psilocybin | 0.3 mg/kg, per oral solution, once | Psilocybin immediately reduced anxiety and depression symptoms for up to 7 weeks post-treatment | Psilocybin decreased cancer-related demonstration and hopelessness while increasing spiritual well-being and quality of life for up to 6.5 months post-treatment. Psilocybin produced positive social effects (increased altruism, positive mood changes and positive changes on attitudes about life and self) | None reported | Ross et al. (2016) |
| 2016 | Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial | Individuals with a life-threatening cancer diagnosis (average age 56.5 y/o, n = 81, 28 males, 25 females) | Randomized, double-blind, crossover | Psilocybin | Low doses: 1 or 3 mg/70 kg High doses: 22 or 30 mg/70 kg either low or high dose was administered, then after 5 weeks the other dosage was administered | High-dose psilocybin elicited a clinical and self-reported decrease in anxiety (including death anxiety) and depressed mood, and an increase in quality of life and optimism. Effects were still present in >80% of individuals at a 6-months follow-up evaluation | No serious adverse effects. Some minor adverse effects (such as psychological discomfort, elevated blood pressure, nausea occurred during the psilocybin session | Griffiths et al. (2016) |
| 2017 | Effect of Psilocybin on Empathy and Moral Decision-Making | Healthy volunteers (20–38 y/o, average 26.72 y/o, n = 32, 17 males, 15 females) | Randomized, double-blind, placebo-controlled, within-subject | Psilocybin | 0.215 mg/kg, per oral solution | Psilocybin increases explicit and implicit emotional empathy compared with placebo | Psilocybin does not modify cognitive empathy compared to placebo | None reported | Polisky et al. (2017) |

(Continued on following page)
TABLE 1 | Recent (2008–2021) clinical trials assessing social behaviour-related effects of psychedelics in neurotypical (non-ASD) individuals

| Year | Title | Cohort | Design | Compound | Regimen (dose, frequency, route of administration) | Main outcomes | Side effects | Ref |
|------|-------|--------|--------|----------|---------------------------------------------------|----------------|-------------|-----|
| 2017 | Pellicott, Grif | Healthy volunteers, support for spiritual practice (n = 75) | Randomized, double-blind, placebo-controlled | Psilocybin | Very low dose - Psilocybin 1 mg/70 kg ($0.0143$ mg/kg) oral solution, twice 1 month apart; n = 25; High dose - Psilocybin 20 and 30 mg/70 kg ($0.29$ mg/kg and $0.43$ mg/kg) respectively in session 1 and 2, 1 month apart; n = 25; High support for spiritual practice, n = 25) | Individuals receiving high dose psilocybin score higher for altruistic/positive social effects than those receiving low dose psilocybin | None reported | Griffith et al. (2018) |
| 2017 | Long-term follow-up of psilocybin-facilitated smoking cessation | Individuals with tobacco addiction (average 51 y/o, n = 15, 10 males, 5 females) | Open label pilot study (follow-up) | Psilocybin | 20 and 30 mg/70 kg, two-three times | Altruistic/positive social effects scores remain significantly higher compared to baseline at 12 months follow-up after the first administration | Physiological adverse effects limited to mild post-session headache, and modest acute elevations in blood pressure and heart rate. Some participants experienced challenging (fearful, anxiety-provoking) psilocybin session experiences. These effects resolved by the end of the drug session via interpersonal support from study staff | Johnson et al. (2017) |
| 2018 | Role of the 5-HT₁₅ Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study | Healthy volunteers (20–34 y/o, n = 24, 18 males, 6 females) | Randomized, double-blind, placebo-controlled, within-subject | LSD | LSD 100 µg, once, per oral solution | LSD loses self-boundaries, reducing neural response to self- versus other-initiated real-time social interaction. LSD’s reduction in brain activity in regions implicated in self-processing and social cognition was correlated with subjective drug effects | No serious adverse events | Poller, Schiabacchi, et al. (2018) |
| 2018 | Long-lasting subjective effects of LSD in normal subjects | Healthy volunteers (n = 16) | Randomized, double-blind, placebo-controlled, within-subject (follow-up) | LSD | 205 µg, once, per oral solution | LSD increases ratings of altruistic/positive social effects after 1 and 12 months | None reported | Schmid and Larché, (2018) |
| 2019 | Psilocybin and MDMA reduce costly punishment in the Ultimatum Game | Healthy volunteers (male, n = 20) | Open-label, within-participant design | Psilocybin | 2 mg per intravenous infusion over 2 min (test performed 60 min later) | Psilocybin increases one’s concern for the outcome of interacting partners | None reported | Galgay et al. (2018) |
| 2019 | Acute subjective and behavioural effects of microdoses of LSD in healthy human volunteers | Healthy volunteers (18–40 y/o, n = 20, 9 males, 12 females) | Randomized, double-blind, placebo-controlled, within-subject | LSD | LSD 6.5, 13, or 26 µg per oral solution with tartaric acid (0.5 ml sublingual) | Dose-related subjective drug effects. LSD (26 µg) increased vigor and marginally decreased the positivity ratings for positive pictures. No other effects on mood, cognition or physiological measures. | Trend towards increased anxiety with 26 µg dose | Bebnath et al. (2019) |
| 2019 | Replication and extension of a model predicting response to psilocybin | 183 valid responses (n = 87 males, n = 85 females), Average age 31.3 y/o, range 18–70 years | Retrospective survey | Psilocybin (dried mushrooms in pieces, dried pink mushrooms, fresh mushrooms, synethalzed psilocybin) Other unprescribed (such as cannabis, opiate, alcohol, stimulants), and prescribed (antidepressant, anti-tycic, blood pressure medications) substances ingested by some of the respondents | Various amounts ingested in the previous 12 months | Having a complete mystical experience is associated with higher post-treatment scores of empathy and social concern. Surrender and preoccupation are the psychological states that produce the greatest (respectively positive and negative) responses | None reported | Russ et al. (2019) |

(Continued on following page)
| Year | Title                                                                 | Cohort                                                                 | Design                                                                 | Compound                  | Regimen (dose, frequency, route of administration) | Main outcomes                                                                 | Side effects                                                                 | Ref               |
|------|----------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------|----------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------|------------------|
| 2019 | Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being | Volunteers attending a psilocybin retreat (average 34.8 y/o, n = 55, 24 males, 26 females) | Observational naturalistic study                                      | Psilocybin-containing truffles | 34.2 g average of psilocybin-containing truffles in tea form, once. Psilocybin content 0.127 mg/G of truffle (content in 34.2 g = 4.34 mg psilocybin), Psilocin 0.7 mg/G of truffle (content in 34.2 g = 23.9 mg psilocin), Truffles crushed and boiling hot ginger tea added. Truffles remain in the cup eaten optionally | Increased emotional empathy (concern for faces depicting negative emotional sub-acutely the morning after but not after 7 days), Increased implicit arousal in response to faces depicting positive and negative emotional content the morning after increased implicit arousal in response to faces depicting negative but not positive emotional content after 7 days | None reported | Mason et al. (2019) |
| 2019 | Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada | Indigenous members of a rural Coast Salish community in British Columbia (BC), Canada (19–65 y/o, mean: 38 y/o, n = 11, 6 males and 5 females) | Observational naturalistic study | Ayahuasca | Ayahuasca (50–100 ml, twice over 2 days) | Some of the participants reported improved emotional openness at 6 months follow-up, Some of the participants improved their social relationships and had better communication with friends and family at 6 months follow-up | None reported | Angerto et al. (2019) |
| 2020 | LSD-induced increases in social adaptation to opinions similar to one’s own are associated with stimulation of serotonin receptors | Healthy volunteers (male and female, 20 y/o to 40 y/o, average 25.25 y/o, n = 24, 18 males, 6 females) | Double blind, placebo-controlled, within subjects | LSD ketanserin | LSD 100, 150, 200 μg, once, per oral solution ketanserin pretreatment (60 min prior) 40 mg, once, per oral solution ketanserin 20 mg, once, per oral solution | LSD increases the adaptation to the opinions of others if they are similar to one’s own, LSD modulates neuronal activity in the mPFC during social feedback processing and not during social decision-making (blocked by ketanserin) The magnitude of LSD-induced social adaptation change is associated with personality, Patients with higher neuroticism scores adapt more strongly after LSD administration, LSD has the strongest impact on social cognition in patients with lower sociability and higher neuroticism scores at baseline | No substantial side effects acutely and after 3 months, Transient mild headaches (1 participant) after drug effects had worn off, Transient sleep disturbances for the first two nights after drug administration (1 participant) | Duerler et al. (2022) |
| 2021 | Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin | Healthy volunteers (25–52 y/o, average age: 29 y/o, n = 16, 8 males, 8 females) | Double blind, placebo-controlled, crossover design | LSD ketanserin | LSD 25, 50, 100, or 200 μg, once, per oral solution ketanserin 20 mg, once, per oral solution | LSD dose-dependently increased explicit and implicit emotional empathy, LSD 200 μg significantly increased emotional empathy compared to placebo ketanserin did not significantly reduce the LSD-induced increase in empathy, LSD increased blood oxytocin levels 1 and 3 h after drug intake, and this effect was blocked by ketanserin administration | None reported | Holow, Avedisian, et al. (2021) |
### TABLE 2

| Year | Title | Cohort | Design | Compound | Regimen (dose, frequency, route of administration) | Main outcomes | Side effects | Ref |
|------|-------|--------|--------|----------|-------------------------------------------------|---------------|-------------|-----|
| 1961 | Treatment of Autistic Schizophrenic Children with LSD-25 and UML-491 | Hospitalized “autistic-schizophrenic” children (n = 14, 11 boys, 3 girls, 6-11.5 years old) | Open label | LSD | Acute: 25 µg, intramuscular; Repeated: 100 µg, per oral solution, once per week in the early morning. Subsequently increased to 100 µg per oral solution 2 to 3 times per week. | Increased body awareness | No adverse side effects reported. | Boder et al. (1961) |
| 1962 | Autistic Schizophrenic Children, An Experiment in the Use of D-Lysergic Acid Diethylamide (LSD-25) and Polyclon on Hospitalized Severely Emotionally Disturbed Children | “Autistic-schizophrenic” children (n = 12, 10 boys, 2 girls, aged 5 years 11 months to 11 years 10 months) | Open label | LSD | 100 µg (1 girl), 50 µg, 1 boy 200 µg; per oral solution, once or twice. | Increased sociality, decreased aggressive behavior, improved communicative abilities | Increased body awareness, decreased aggressive behavior | Friedman et al. (1962) |
| 1963 | Interim report on Research project: An Investigation to Determine Therapeutic Effectiveness of LSD-25 and Psilocybin on Hospitalized Severely Emotionally Disordered Children | Hospitalized Severely Emotionally Disturbed Children (n = 12, 4 y 10 m—12 y 11 m, average 9 y 10 m) | Unknown | LSD | Psilocybin (0.25–4.0 µg, typical dosage 200–300 µg) daily; Polyclon (15 mg) | Increased responsiveness to adults | Some adverse effects (e.g., nausea) | Fish and Castle (1963) |
| 1963 | LSD and UML treatment of hospitalized disturbed children | Hospitalized children (n = 55). Half displayed autism spectrum disorder features and half displayed psychotic features | Open label | LSD | LSD gradually increased from 50 to 150 µg daily, divided into two doses; UML gradually increased from 6 to 12 mg daily, divided into two doses | Increased responsiveness to environmental stimuli; Decreased aggressive behavior | No serious adverse events | Boder et al. (1963) |
| 1966 | Modification of autistic behavior with LSD-25 | “Autistic” twin males (4 years 9 months old at study start, 5 years 2 months at study end) | Double-blind, placebo-controlled | LSD | LSD 50 µg per oral solution, 9 treatments, twice weekly; chlorpromazine to terminate the LSD effects after 3 h | Increased eye-to-face contact during LSD sessions | None reported | Simmons et al. (1966) |

(Continued on following page)
### TABLE 2 (Continued) Early clinical trials (1961–1970) assessing the use of psychedelics in “autistic schizophrenic” children. The terms “autistic” and “schizophrenic” do not reflect the currently approved terminology of the DSM-V, but rather the terminology that was used at the time of these early studies.

| Year | Title | Cohort | Design | Compound | Regimen (dose, frequency, route of administration) | Main outcomes | Side effects | Ref |
|------|-------|--------|--------|----------|------------------------------------------------|---------------|-------------|-----|
| 1966 | The Treatment of Childhood Schizophrenia with LSD and UML | “Autistic”, regressed, verbal, psychotic and “schizophrenic” (different groups) pre- and post-puberty male and female children 6–15 years of age (total n = 54) | Open label | LSD, UML | LSD, 100–150 µg, daily in 2 doses UML 12 mg daily, divided in 2 doses. Duration of treatment: 2–18 months, with an average of 9 months | Prepuberty “autistic” boys All participants showed some mild (variable) degree of favorable responses with slow and steady progression Participants were happier following the ingestion of the drug and this tended to carry over through the whole day. Participants became spontaneously more playful with boys, other children and adults. Participants sought and responded to physical contact and affection. Decreased overall aggressive behaviour. Food habits and toilet training improved in some participants. Improved skin color and overall physical health. Decreased rhythmic and stereotyped behaviour. Increased responsiveness to environmental cues, stimuli and patterns. Increased laughter behaviour. Increased maturity in the Vineland Social Maturity Scale (the authors suggest that the real improvements are underestimated by this scale). Prepuberty “autistic” girls No detectable improvement in maturation or social maturity. Two of the three girls seemed brighter and improved in color, weight gain, and eating and toilet habits. Postpuberty “autistic” boys Similar responses to younger “autistic” children although responses are attenuated compared to prepuberty “autistic” boys. Increased typical behaviours such as climbing, ball bouncing and rocking. Strong improvement in verbalization and speech appropriateness in one boy. For the first time, some children attempted to contact approach adults. | In “autistic” prepuberal boys, no regressions were observed although some children had episodic occurrences of aggressive contact with other children and feces smearing. One of the “autistic” prepuberal girls became too active and aggressive towards other children. Reserpine was administered with LSD to counteract these effects. Some of the “autistic” postpuberal boys attempted to interact with others via biting and pinching. | Bender et al. (1966) |
| 1970 | The Psycholytic Treatment of a Childhood Schizophrenic Girl | Case report of the “autistic-schizophrenic” girl of the clinical trial by Freedman et al., 1962 | Open label | LSD, Psilocybin | 16 treatments over 11 months with LSD alone (50–300 µg, n = 13 treatments), psilocybin alone (10–20 mg, n = 2 treatments), or LSD (300 µg) + psilocybin (10 mg, n = 1 treatment) Methedrine (5 mg) and Librium (10–25 mg) given in some instances in combination with LSD (300–300 µg) and psilocybin (10 mg) + LSD (200 µg). | Increased motor and verbal behaviour. Increased desire for physical contact, the child was delighted and excited with perceptual changes. Decreased repetitive movements. Enhanced sense of humor, she was able to feel and relate to others in a “normal” way. At the end of the treatment she reached a state of deep acceptance and profound feelings of love and personal integration. She ceased her isolated, “autistic” behaviour, talked normally, and helped other children. Despite scarce follow-up records, she seemed to have stabilized at 5 years follow-up. | Mood swings including. Anxious behaviour, restless behaviour, angry behaviour, stuffing objects in her mouth. Emergence of internal conflict and anger led to anxious, agitated, and self-harming behaviour. At the end of treatment 4, she became very violent and tried to choke herself as well as others. | Fisher, (1970) |
Altogether, we suggest that psychedelics may target the dysregulated thalamocortical connectivity and thalamic neuronal firing in individuals with ASD. However, it is also true that the thalamocortical dysregulations in individuals with ASD may concurrently limit the behavioural effects of psychedelics (such as changes in social behaviour) that are mediated by thalamocortical signaling. For instance, mice with embryonic-stage deletions of the Tuberous Sclerosis Complex 1 (Tsc1) gene (a standard preclinical model of ASD) had an overabundance and greater diffusion of thalamic projections to the somatosensory cortex (Normand et al., 2013). Since structural thalamocortical connectivity is profoundly altered in this ASD model, the response of this circuit to the administration of psychedelics may also be altered. Thus, any cognitive effects of psychedelics mediated by their ability to modulate thalamocortical signaling may be significantly different in people with ASD, potentially limiting their therapeutic effects.

**CLINICAL TRIALS OF PSYCHEDELICS IN CHILDREN WITH ASD (1961–1970)**

Prior to the classification of psychedelics as Schedule 1 Controlled Substances in 1970, these substances were tested in the treatment of children with ASD in order to assess their efficacy in relieving treatment-refractory ASD-like behaviours. Importantly, these individuals were classified as “autistic-schizophrenic” (Bender et al., 1961; Freedman et al., 1962; Bender et al., 1966; Fisher, 1970), and “severely emotionally disturbed” (Fisher and Castile, 1963). Thus, they may not have necessarily been diagnosed with ASD using contemporary diagnostic criteria, imposing a significant limitation on these findings (reviewed and summarized in Table 2). Although significant methodological and ethical shortcomings are evident through the lens of modern clinical and ethical research standards, this early work is being re-examined to extrapolate potentially meaningful data which could inform contemporary research.

Most of these studies involved a regimen of LSD given at medium to high doses (25–400 µg), with schedules ranging from a single administration to daily administrations for up to 18 months. The most effective results were observed when daily or weekly LSD was given over relatively extended periods of time (Bender et al., 1961). Greater improvements were observed when the therapist was more actively involved with the children; when they were given the possibility to experience meaningful interpersonal psychotherapeutic interactions; and when the settings were free of artificial or experimental restrictions. When the children were taken off the drug, their behaviour regressed, but not to the extent observed previously (Bender et al., 1963).

Psychedelic-assisted therapy in children with ASD resulted in a variety of clinical improvements: enhanced mood, sociability, and affectionate behaviour; increased emotional closeness, relatedness, and responsiveness to others; increased desire to communicate and interest in the surrounding environment; relief of perceptual hypersensitivity; improved speech and vocabulary; increased playfulness, smiling, and laughing; increased eye and face-gazing behaviour; decreased aggressive and repetitive behaviours; and improved sleep patterns.

Although the aforementioned effects of psychedelics are desirable in the treatment of ASD, adverse effects of varying severity were also reported. Some of the children experienced rapid mood swings, ataxia, and moderate to severe anxiety, with at least one case of a “panic-like state” (Bender et al., 1961; Freedman et al., 1962). One girl experienced two episodes of seizures during LSD treatment (Fisher and Castile, 1963). Some of the children displayed increased biting and pinching behaviour, some engaged in aggressive behaviour even after the effects of the drug had worn off, and some had difficulty sleeping in the days following administration (Bender et al., 1961; Freedman et al., 1962; Bender et al., 1963; Fisher and Castile, 1963; Bender et al., 1966; Fisher, 1970). In one “autistic-schizophrenic” girl receiving LSD and psilocybin, the emergence of internal anxiety led to acute anxious, aggressive, and self-harming behaviour (Fisher, 1970).

Given that certain individuals with ASD present atypical behavioural characteristics such as increased aggression (Fitzpatrick et al., 2016) and epilepsy (Tuchman and Rapin, 2002), it is not entirely surprising that psychedelic treatment triggered aggressive behaviour (Bender et al., 1966) and seizures (Fisher and Castile, 1963) in some of the children. Consequently, serious precautions must be taken when using psychedelic treatments in these vulnerable populations.

Another potential risk is the potential for psychedelics to induce psychosis and/or schizophrenia. The prevalence of schizophrenia is significantly higher in people with ASD compared to neurotypical individuals (Zheng et al., 2018). Since psychedelic use is associated with the development of psychosis in people with genetic predispositions (Breakey et al., 1974; Vardy and Kay, 1983), the risk of psychosis and schizophrenia must be carefully considered when assessing the potential adverse effects of psychedelic administration in this population. Altogether, although some therapeutic effects of psychedelics in children with ASD have been reported, the extended list of reported adverse effects demands caution.

**CONCLUSION**

Due to the limited treatment options for ASD, the development of novel therapies is warranted. Clinical and preclinical trials suggest that psychedelics may improve social behaviour and decrease the burden of co-occurring diagnoses in ASD by targeting synaptic function, serotonin signaling, PFC activity, and thalamocortical signaling. Early clinical trials in childhood ASD suggest that psychedelics might hold therapeutic potential; however, the side effects encountered represent potential limitations to this treatment. It is possible that psychedelics may alleviate a few core social-behavioural features in individuals with ASD, such as social anxiety, but carefully performing a risk-to-benefit assessment is crucial due to the severity of their potential side effects.

Individuals with ASD represent a highly heterogeneous demographic; therefore, only certain subsets of individuals...
with ASD may respond well to psychedelic treatment options. Clinical trials must proceed with caution because this population is also comprised of children and some individuals with intellectual disabilities, for which obtaining informed consent is a challenge. Future studies must make these considerations when determining if some of the positive findings obtained in the “first wave” of psychedelic research in ASD can be validated when employing contemporary scientific and ethical standards.

AUTHOR CONTRIBUTIONS

Participated in Research Design: AM, AI, DDG, and GG. Wrote or contributed to the writing of the article: AM, AI, DDG, and GG.

REFERENCES

Adamsen, D., Ramaekers, V., Ho, H. T., Britschgi, C., Rüfenacht, V., Meili, D., et al. (2014). Autism Spectrum Disorder Associated with Low Serotonin in CSF and Mutations in the SLC29A4 Plasma Membrane Monooamine Transporter (PMAT) Gene. Mol. Autism 5, 43, 2014. Epub 2014/01/01. doi:10.1186/2040-2392-5-43

American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub.

Anderson, G. R., Galfin, T., Xu, W., Aoto, J., Malenka, R. C., and Südhof, T. C. (2012). Candidate Autism Gene Screen Identifies Critical Role for Cell-Adhesion Molecule CASPR2 in Dendritic Arborization and Spine Development. Proc. Natl. Acad. Sci. U S A. 109, 18120–18125. Epub 2012/10/18. doi:10.1073/pnas.1216598109

Anderson, S. W., Bechara, A., Damasio, H., Tranel, D., and Damasio, A. R. (1999). Impairment of Social and Moral Bvaheaviour related to Early Damage in Human Prefrontal Cortex. Nat. Neurosci. 2, 1032–1037. Epub 1999/10/20. doi:10.1016/S1097-6277(99)70074-7

Argento, E., Capler, R., Thomas, G., Lucas, P., and Tupper, K. W. (2019). Exploring Ayahuasca-Assisted Therapy for Addiction: A Qualitative Analysis of Preliminary Findings Among an Indigenous Community in Canada. Drug Alcohol. Rev. 38, 781–789. Epub 2019/09/07. doi:10.1111/dar.12985

Ayub, R., Sun, K. L., Flores, R. E., Lam, V. T., Jo, B., Saggar, M., et al. (2021). Thalamocortical Connectivity Is Associated with Autism Symptoms in High-Functioning Adults with Autism and Typically Developing Adults. Transl Psychiatry 11, 93. doi:10.1038/s41398-021-01221-0

Barbosa, P. C., Cazorla, I. M., Gligio, J. S., and Strassman, R. (2009). A Six-Month Prospective Evaluation of Personality Traits, Psychiatric Symptoms and Quality of Life in Ayahuasca-Naive Subjects. J. Psychoactive Drugs 41, 205–212. doi:10.1080/02791072.2009.10400530

Barre, A., Berthoux, C., De Bundel, D., Valjent, E., Bockaert, J., Marin, P., et al. (2016). Presynaptic Serotonin 2A Receptors Modulate Thalamocortical Plasticity and Associative Learning. Proc. Natl. Acad. Sci. U S A. 113, E1382–E1391. Epub 2016/02/24. doi:10.1073/pnas.1525586113

Bassell, G. J., and Warren, S. T. (2008). Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function. Neuron 60, 201–214. Epub 2008/10/30. doi:10.1016/j.neuron.2008.10.004

Bedi, G., Hyman, D., and de Wit, H. (2010). Is Ecstasy an "empathogen"? Effects of 3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others. Biol. Psychiatry 68, 1134–1140. Epub 2010/10/16. doi:10.1016/j.biopsych.2010.08.003

Bender, L., Faretta, G., and Csikszentmihalyi, M. (1966). In Biological Treatment of Mental Illness: Proceedings of the II International Conference of the Manfred Sakel Foundation. Editor M. Rinkel (New York: New York Academy of Medicine).

Bender, L., Faretta, G., and Cobrinik, L. (1963). LSD and UML Treatment of Hospitalized Disturbed Children. Recent Adv. Biol. Psychol. 5, 84–92.

FUNDING

This work was supported by grants from the CIHR (Canadian Institutes of Health Research, #173556), RQSHA (Réseau Québécois sur le Suicide, les Troubles de l’Humeur et les Troubles Associés, #20067). AM is a recipient of the FRQS and Quebec Autism Research Training (QART) Program Master’s fellowships. AI is a recipient of the CIHR, FRQS and QART postdoctoral fellowships. DDG was a recipient of the FRQS and CIHR postdoctoral fellowships.

ACKNOWLEDGMENTS

We thank Molly Kennedy for editing and proof-reading the article.

Bender, L., Goldsmith, L., and Sankar, D. V. (1961). Treatment of Autistic Schizophrenic Children with LSD-25 and UML-491. Recent Adv. Biol. Psychiatry 4, 170–179. Epub 1961/01/01. doi:10.1016/0797-1484/8306-2.17

Bershad, A. K., Schepers, S. T., Bremmer, M. P., Lee, R., and de Wit, H. (2019). Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol. Psychiatry 86, 792–800. doi:10.1016/j.biopsych.2019.05.019

Berthoux, C., Barre, A., Bockaert, J., Marin, P., and Bécamel, C. (2019). Sustained Activation of Postsynaptic 5-HT2A Receptors Gates Plasticity at Prefrontal Cortex Synapses. Cereb. Cortex 29, 1659–1669. Epub 2018/06/20. doi:10.1093/cercor/bhy064

Boylan, C. B., Blue, M. E., and Hohmann, C. F. (2007). Modeling Early Cortical Serotonergic Deficits in Autism. Behav. Brain Res. 176, 94–108. Epub 2006/10/13. doi:10.1016/j.bbr.2006.08.026

Brandenburg, C., and Blatt, G. J. (2019). Differential Serotonin Transporter (5-HTT) and 5-HT2 Receptor Density in Limbic and Neocortical Areas of Adults and Children with Autism Spectrum Disorders: Implications for Selective Serotonin Reuptake Inhibitor Efficacy. J. Neurochem. 151, 642–655. Epub 2019/07/22. doi:10.1111/jn.14832

Breakey, R. W., Goodell, H., Lorenz, P. C., and McHugh, P. R. (1974). Hallucinogenic Drugs as Precipitants of Schizophrenia. Psychol. Med. 4, 255–261. Epub 1974/08/01. doi:10.1017/s0033291700042938

Brumback, A. C., Ellwood, I. T., Kjaerby, C., Ifraichi, J., Robinson, S., Lee, A. T., et al. (2018). Identifying Specific Prefrontal Neurons that Contribute to Autism-Associated Abnormalities in Physiology and Social Behavior. Mol. Psychiatry 23, 2078–2099. doi:10.1038/mp.2017.213

Brummelte, S., Mc Glanaghy, E., Bonnin, A., and Oberlander, T. F. (2017). Developmental Changes in Serotonin Signaling: Implications for Early Brain Function, Behavior and Adaptation. Neuroscience 342, 212–231. Epub 2016/02/26. doi:10.1016/j.neuroscience.2016.02.037

Cameron, L. P., Benson, C. J., DeFelice, B. C., Fiehn, O., and Olson, D. E. (2019). Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chem. Neurosci. 10, 3261–3270. Epub 2019/03/05. doi:10.1021/acschemneuro.8b00692

Carhart-Harris, R., Glassfield, B., Watts, R., Baker-Jones, M., Murphy-Reiner, A., Murphy, R., et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. N. Engl. J. Med. 384, 1402–1411. Epub 2021/04/15. doi:10.1056/NEJMa2032994

Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., et al. (2018). Psilocybin with Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up. Psychopharmacology (Berl) 235, 399–408. Epub 2017/11/10. doi:10.1007/s00213-017-4771-x

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Cash, A., et al. (2012). Neural Correlates of the Psychedelic State as Determined by fMRI Studies with Psilocybin. Proc. Natl. Acad. Sci. U S A. 109, 2138–2143. doi:10.1073/pnas.1119598109
Tuchman, R., and Rapin, I. (2002). Epilepsy in Autism. *Lancet Neurol.* 1, 352–358. Epub 2003/07/10. doi:10.1016/s1474-4422(02)00160-6

Vardy, M. M., and Kay, S. R. (1983). LSD Psychosis or LSD-Induced Schizophrenia? A Multimethod Inquiry. *Arch. Gen. Psychiatry* 40, 877–883. Epub 1983/08/01. doi:10.1001/archpsyc.1983.01790070067008

Vesuna, S., Kauvar, I. V., Richman, E., Gore, F., Oskotsky, T., Sava-Segal, C., et al. (2020). Deep Posteromedial Cortical Rhythm in Dissociation. *Nature* 586, 87–94. Epub 2020/09/18. doi:10.1038/s41586-020-2731-9

Waiter, G. D., Williams, J. H., Murray, A. D., Gilchrist, A., Perrett, D. I., and Whiten, A. (2004). A Voxel-Based Investigation of Brain Structure in Male Adolescents with Autistic Spectrum Disorder. *Neuroimage* 22, 619–625. doi:10.1016/j.neuroimage.2004.02.029

Wang, X., McCoy, P. A., Rodriguez, R. M., Pan, Y., Je, H. S., Roberts, A. C., et al. (2011). Synaptic Dysfunction and Abnormal Behaviors in Mice Lacking Major Isoforms of Shank3. *Hum. Mol. Genet.* 20, 3093–3108. Epub 2011/05/12. doi:10.1093/hmg/ddr212

Weiststaub, N. V., Zhou, M., Lira, A., Lambe, E., González-Maeso, J., Hornung, J. P., et al. (2006). Cortical 5-HT2A Receptor Signaling Modulates Anxiety-like Behaviors in Mice. *Science* 313, 536–540. Epub 2006/07/29. doi:10.1126/science.1123432

Woodward, N. D., Giraldo-Chica, M., Rogers, B., and Cascio, C. J. (2017). Thalamocortical Dysconnectivity in Autism Spectrum Disorder: An Analysis of the Autism Brain Imaging Data Exchange. *Biol. Psychiatry Cogn. Neurosci. Neuroimaging* 2, 76–84. doi:10.1016/j.bpsc.2016.09.002

Zheng, Z., Zheng, P., and Zou, X. (2018). Association between Schizophrenia and Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. *Autism Res.* 11, 1110–1119. Epub 2018/10/05. doi:10.1002/aur.1977

Conflict of Interest: DDG is a consultant at Diamond Therapeutics Inc., Toronto, ON, Canada. GG and DDG are inventors of a provisional patent regarding the use of LSD.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.